AG
FATE icon

Advisor Group’s Fate Therapeutics FATE Stock Holding History

Advisor Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$16K Hold
800
– – ﹤0.01% 4079
2019
Q3 		$12K Hold
800
– – ﹤0.01% 4239
2019
Q2 		$16K Sell
800
-300
-27% -$5.41K ﹤0.01% 4102
2019
Q1 		$19K Hold
1,100
– – ﹤0.01% 4007
2018
Q4 		$14K Sell
1,100
-415
-27% -$5.79K ﹤0.01% 4018
2018
Q3 		$24K Sell
1,515
-85
-5% -$1K ﹤0.01% 3771
2018
Q2 		$18K Hold
1,600
– – ﹤0.01% 3768
2018
Q1 		$16K Sell
1,600
-700
-30% -$6.71K ﹤0.01% 3815
2017
Q4 		$14K Hold
2,300
– – ﹤0.01% 3888
2017
Q3 		$9K Sell
2,300
-300
-12% -$1.02K ﹤0.01% 4038
2017
Q2 		$8K Buy
2,600
+600
+30% +$2.3K ﹤0.01% 4033
2017
Q1 		$9K Hold
2,000
– – ﹤0.01% 3834
2016
Q4 		$5K Hold
2,000
– – ﹤0.01% 3920
2016
Q3 		$6K Buy
+2,000
New +$4.85K ﹤0.01% 3808

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Advisor Group's FATE Position: Q4 2019 in Review

Advisor Group held its Fate Therapeutics (FATE) position steady in Q4 2019 at 800 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #4079.

Advisor Group first reported a position in FATE in Q3 2016 and has held it in 14 quarters since. The position peaked at $24K in Q3 2018. 147 funds tracked by Wall St. Rank hold FATE as of Q4 2019.

  • Advisor Group held 800 shares of Fate Therapeutics worth $16K as of Q4 2019.
  • Advisor Group left its Fate Therapeutics share count unchanged in Q4 2019.
  • Fate Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4079 holding.
  • Advisor Group first reported a position in Fate Therapeutics in Q3 2016 and has held it in 14 quarters since.
  • Advisor Group's Fate Therapeutics position peaked at $24K in Q3 2018.
  • 147 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.